Innocan
Pharma Corporation
1015,
926 – 5 Avenue SW
Calgary,
Alberta T2P 0N7, Canada
November
10, 2025
Via
EDGAR
Securities
and Exchange Commission
Division
of Corporate Finance
100
F Street, NE
Washington,
D.C. 20549
| |
RE: |
Innocan Pharma Corporation (CIK 0001889791) |
| |
|
Registration Statement No. 333-288899 on Form F-1
(the “Registration Statement”) |
Ladies
and Gentlemen:
Reference
is made to the Registration Statement on Form F-1 (Amendment No. 4) (File No. 333-288899) filed by Innocan Pharma Corporation on October
22, 2025 (the “Registration Statement”).
Pursuant
to Rule 473(c) of the Securities Act of 1933 (the “Act”), the following delaying amendment, prescribed by Rule 473(a) of
the Act, is hereby incorporated into the facing page of the Registration Statement:
“The
registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective
on such date as the Commission, acting pursuant to said Section 8(a), may determine.”
Should
you have any questions regarding the Registration Statement, please feel free to contact the undersigned at +1 312-364-1633.
Yours
sincerely,
| |
Very truly yours, |
| |
|
| |
INNOCAN PHARMA CORPORATION |
| |
|
| |
By: |
/s/
Iris Bincovich |
| |
|
Iris Bincovich |
| |
|
Chief Executive Officer |
cc:
David Huberman (Greenberg Traurig, LLP)
